Apis Capital Advisors LLC Acquires New Holdings in Celcuity, Inc. $CELC

Apis Capital Advisors LLC bought a new position in Celcuity, Inc. (NASDAQ:CELC) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 776,000 shares of the company’s stock, valued at approximately $38,334,000. Celcuity comprises approximately 8.5% of Apis Capital Advisors LLC’s investment portfolio, making the stock its biggest position. Apis Capital Advisors LLC owned approximately 1.68% of Celcuity at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Creative Planning acquired a new position in Celcuity during the second quarter valued at approximately $177,000. Intech Investment Management LLC lifted its stake in shares of Celcuity by 5.2% in the second quarter. Intech Investment Management LLC now owns 14,855 shares of the company’s stock worth $198,000 after buying an additional 734 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Celcuity by 1.2% in the second quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock worth $570,000 after buying an additional 503 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Celcuity during the 2nd quarter worth $169,000. Finally, Saturn V Capital Management LP boosted its holdings in shares of Celcuity by 8.4% during the 2nd quarter. Saturn V Capital Management LP now owns 1,185,520 shares of the company’s stock worth $15,827,000 after buying an additional 91,843 shares during the period. Institutional investors own 63.33% of the company’s stock.

Celcuity Trading Up 3.1%

Shares of CELC stock opened at $114.22 on Friday. The firm has a market capitalization of $5.28 billion, a P/E ratio of -31.12 and a beta of 0.38. Celcuity, Inc. has a 1 year low of $7.57 and a 1 year high of $120.32. The firm’s fifty day simple moving average is $108.80 and its 200 day simple moving average is $87.09. The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 2.74.

Insider Transactions at Celcuity

In other news, Director David Dalvey sold 20,000 shares of the business’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $120.03, for a total transaction of $2,400,600.00. Following the transaction, the director owned 90,000 shares in the company, valued at approximately $10,802,700. The trade was a 18.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 15.77% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

CELC has been the topic of several recent analyst reports. Wolfe Research reiterated an “outperform” rating and issued a $110.00 target price on shares of Celcuity in a report on Thursday. Jefferies Financial Group upped their price target on shares of Celcuity from $108.00 to $134.00 and gave the company a “buy” rating in a report on Tuesday, December 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celcuity in a research report on Wednesday, January 21st. Needham & Company LLC lifted their price objective on Celcuity from $95.00 to $122.00 and gave the stock a “buy” rating in a research note on Tuesday, March 10th. Finally, HC Wainwright reissued a “neutral” rating and set a $94.00 price objective (up from $77.00) on shares of Celcuity in a research report on Monday, November 17th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Celcuity currently has an average rating of “Moderate Buy” and an average price target of $108.63.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.